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To improve its poor aqueous solubility and stability, the potential chemotherapeutic drug quercetin was encapsulated
in soluplus polymeric micelles by a modified film dispersion method. With the encapsulation efficiency over 90%, the
quercetin-loaded polymeric micelles (Qu-PMs) with drug loading of 6.7% had a narrow size distribution around mean
size of 79.00 ± 2.24 nm, suggesting the complete dispersibility of quercetin in water. X-ray diffraction (XRD) patterns
illustrated that quercetin was in amorphous or molecular form within PMs. Fourier transform infrared spectroscopy
(FTIR) indicated that quercetin formed intermolecular hydrogen bonding with carriers. An in vitro dialysis test showed
the Qu-PMs possessed significant sustained-release property, and the formulation was stable for at least 6 months
under accelerated conditions. The pharmacokinetic study in beagle dogs showed that absorption of quercetin after oral
administration of Qu-PMs was improved significantly, with a half-life 2.19-fold longer and a relative oral bioavailability of
286% as compared to free quercetin. Therefore, these novel soluplus polymeric micelles can be applied to encapsulate
various poorly water-soluble drugs towards a development of more applicable therapeutic formulations.
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Oral administration is by far the easiest and most ac-
ceptable route of drug delivery, especially for the long-
term medication of patients [1]. But about 40% of the
approved active molecules have low solubility, resulting
in poor oral bioavailability. Many efforts have been de-
voted to the development of oral sustained-release sys-
tems that can not only improve drug bioavailability
leading to better efficacy and less administration frequen-
cies but also decrease the fluctuation of plasma drug con-
centration to lower side effects [2]. In recent decades,
emerging nanotechnology provides a novel platform to
solve the solubility problem of drugs [3,4]. Especially,
polymeric micelles as a promising drug delivery system is
a new research hotspot [5], most current studies concen-
trated on developing polymeric micelles for injection drug
delivery [6]. Drug-loaded micelles in the systemic circula-
tion characterizes long retention time and excellent tissue* Correspondence: chuanbin_wu@126.com
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in any medium, provided the original work is ppermeability and can gather in the diseased tissue to gain
passive targeting [7,8]. Furthermore, polymeric micelles
with stable, biocompatible, and solubilizing properties
have drawn considerable attention for oral administration.
Polymeric micelles with inner ‘core’ and outer ‘shell’ are
formed by amphiphilic copolymers composed of hydro-
philic and hydrophobic chains that can self-assemble in
water above the critical micelle concentration (CMC) [9].
A polymeric micelle has the ability to encapsulate a hydro-
phobic drug into their cores and deliver the drug to the
desired site at the concentration exceeding the intrinsic
solubility of the drug. Moreover, the encapsulated drug
can be not only protected from contact with the GI con-
tents which likely induce degradation and metabolism but
also conferred with the characteristics of sustained-release
and direct uptake by cells. Many studies have proven that
nanoparticles can transport across the intestinal mem-
brane through paracellular or trancellular routes [10],Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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formulation based on nanosized polymeric micelles was
expected to achieve the advantages of nanoparticles, such
as enhanced permeability and retention (EPR) effects.
Quercetin (3, 3′, 4′, 5, 7-pentahydroxy flavones,
Figure 1A) is a flavonoid compound widely present in
flower, leaf, and fruit of plants such as Sophora japonica
L., Dendranthema morifolium (Ramat.) Tzvel, and Cratae-
gus pinnatifida bunge, with a variety of biological activity
and high medical value [12]. Literature indicates that
quercetin can inhibit the growth and proliferation of a var-
iety of cancer cell lines (human ovarian cancer, breast
cancer, lung cancer, human colon cancer, etc.) [13-16].
Quercetin can also lower the multidrug-resistance in
cancer cells [17,18] and enhance the antitumor effects
of drugs [19,20].
But clinical use of quercetin is limited due to its poor
water solubility and instability in physiological media
[21], leading to poor bioavailability [22]. Polymeric mi-
celles are regarded as excellent candidates for anticancer
drug delivery, and several anticancer drugs delivered by
amphiphilic polymer micelles have already been pre-
ceded to clinical study or market [23,24]. Recently,
polymer micelles have been utilized for quercetin for-
mulation too [25].
Soluplus, an amphiphilic polyvinyl caprolactam-polyvinyl
acetate-polyethylene glycol graft copolymer (Figure 1B),
was introduced by BASF. This graft copolymer has a
polyethylene glycol (PEG) backbone as hydrophilic part
and vinylcaprolactam/vinyl acetate side chains as lipo-
philic structure. So, micelles can be formed in aqueous so-
lution above the CMC of 7.6 mg · L−1 (Figure 1C) [26].
The objective of this study was to develop a nanomi-
celle delivery system by using soluplus and poloxamer
407(F127), which could solubilize quercetin in aqueous
media, reaching the clinically relevant concentration and
delivering quercetin in a controlled manner. The previ-
ously reported preparation method was slightly modified
to produce soluplus micelles with suitable size, charge,
and stable properties. Powder X-ray diffraction (XRD)Figure 1 The structure of quercetin (A), soluplus (B) and formation ofwas employed to identify the physical state of quercetin
in the polymeric micelles. Taking advantage of their
permeation-enhancing effect, the soluplus nanomicelles
were evaluated in vivo as potential vehicles, and the
pharmacokinetic profile of orally administered quer-
cetin encapsulated in micelles was investigated.
Methods
Materials
Soluplus® was friendly supplied by BASF Auxiliary Chem.
Co., Ltd. (Shanghai, China). Poloxamer 407 (PEO98-
POP67PEO98) was obtained from BASF (Ludwigshafen,
Germany). Quercetin (Qu) was purchased from Shanxi
Sciphar Biotech. Co. Ltd. (Shanxi, China). Methanol
(high-performance liquid chromatography (HPLC) grade)
was purchased from Fisher Scientific, Waltham, MA,
USA. Milli-Q grade water purified through a Millipore
system (ELGA LabWater, Sartorius, UK) was used
throughout this study. All solvents were used without
further purification.
Animals
Beagle dogs were obtained from Experimental Animal
Center of Sun Yat-sen University (Guangzhou, China).
Beagle dogs were provided with standard food and water
at will and were exposed to alternating 12-h periods of
light and darkness. Relative humidity and temperature
were maintained at 50% and 25°C, respectively. All care
and handling of animals were performed with the ap-
proval of Institutional Authority for Laboratory Animal
Care of Sun Yat-sen University.
Preparation of quercetin-loaded soluplus polymeric
micelles
Quercetin-loaded polymeric micelles (Qu-PMs) were
formed by a modified film dispersion method using solu-
plus and F127 [27]. Briefly, soluplus (10 mg) and quer-
cetin (7 mg) were dissolved together in organic solvent
acetone, followed by evaporation under reduced pressure
in a rotary evaporator at 35°C. The deionized water wasPMs (C).
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the self-assembly of soluplus and quercetin to form
quercetin-encapsulated polymeric micelles with core-
shell structure (Figure 1C) at 650 rpm. Finally, the pre-
pared Qu-PMs were lyophilized for future application.
Determining the optimum concentration of F127
Then the optimum concentration of F127 required for
preparing the desirable Qu-PMs was determined based
on particle size and encapsulation efficiency.
Determining the optimum stirring time
The optimum time of magnetic stirring for the prepar-
ation of Qu-PMs was determined on the basis of particle
size and encapsulation efficiency.
Optimization of drug loading
Qu-PMs were prepared using different theoretical Qu
loading, i.e., 5%, 7%, and 9% of polymer on the basis of
preliminary experiment, to determine the optimum per-
centage of Qu in soluplus matrix and its effects on par-
ticle size, polydispersity index (PDI), zeta potential, and
encapsulation efficiency of Qu-PMs. The magnetic stir-
ring time (2 h), stabilizer concentration (1% of F127), and
aqueous ratio were kept constant.
Characterization of Qu-PMs
Particle size and zeta potential measurements
The particle size and PDI of Qu-PMs were determined
by using a Malvern Instruments Zetasizer Nano ZS90
(Malvern Instruments, Malvern, UK) on the basis of pho-
ton correlation spectroscopy. The dispersion of Qu-PMs
was diluted in double distilled water and measured at
25°C for analysis. The particle size and PDI were ob-
tained by cumulate analysis using the MALVERN soft-
ware. The Zeta potential of Qu-PMs also measured by
using a Malvern Instruments Zetasizer Nano ZS90
(Malvern Instruments, Malvern, UK). All experiments
were repeated three times.
Transmission electron microscopy
The surface morphology of Qu-PMs was examined
by using a transmission electron microscope (TEM;
H66009IV, Hitachi, Chiyoda-ku, Japan). The dispersion
of Qu-PMs were placed on a copper grid covered with
nitrocellulose, negatively stained with phosphotungstic
acid, and allowed to dry at room temperature.
X-ray diffraction
The X-ray diffraction patterns of pure Qu, void PMs,
physical mixture of void PMs and Qu, and Qu-PMs were
obtained by using an X-ray powder diffractometer (Bruker
AXS, Madison, WI, USA) at a voltage of 40 kV and25 mA with a scanned angle from 5° ≤ 2θ ≤ 50° at a scan
rate of 0.9 · min−1.
Fourier transform infrared spectrometer
The Fourier transform infrared spectroscopy (FTIR)
spectra of Qu, void PMs, physical mixture of void PMs
and Qu, and Qu-PMs were recorded on a Nicolet 5700
FTIR spectroscopy (Thermo, Waltham, MA, USA) using
a Smart OMNI-sampler accessory. The samples were put
on KBr plates. The FTIR spectra were recorded at 1 cm−1
resolution, with the range of 400 to 4,000 cm−1.
Encapsulation efficiency (EE)
The content of Qu encapsulated in PMs was determined
by membrane filter method. 0.5 mL of Qu-PMs was fil-
tered through the 0.22-μm membrane, while non-
encapsulated Qu was retained on the membrane. The
filtrate which contained Qu-PMs was demulsificated
with methanol and analyzed for entrapped Qu content
by high-performance liquid chromatography (HPLC).
All experiments were repeated three times.
In vitro release
In vitro release of Qu from Qu-PMs was undertaken by
the dialysis bag method [28]. The dialysis bags (MWCO
14000, Millipore, Boston, MA, USA) were immersed in
double-distilled water for 24 h prior to loading with 2 mL
of Qu-PMs dispersion or quercetin solution (equivalent to
4 mg of Qu). The loaded bags were putted into a conical
flask and soaked in 100 mL of 35% (v/v) ethanol, and the
flask was placed in a water bath at 37°C ± 0.5°C and stirred
rate of 100 rpm. The release medium (5 mL) was taken
out at time intervals of 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 24.0,
48.0, 72.0, 96.0, 120.0, 144.0, 168.0, 192.0, 216.0, 240 h and
added with the same volume of fresh medium to adjust a
sink condition [29,30]. The content of Qu was determined
by HPLC. Each test was carried out in triplicate.
The mechanism of Qu release from PMs was per-
formed by fitting the release rate data into the following
equations:
Zero‐order model equation : y ¼ k1t þ a1 ð1Þ
First‐order model equation : ln 100 − yð Þ ¼ k2t þ a2 ð2Þ
Higuchi’s square‐root equation : y ¼ k3t0:5 þ a3 ð3Þ
Here y represents the accumulative release percentage;
t sampling time; k1, k2, and k3 release rate constants for
Equations 1, 2, and 3, respectively; a1 ~ a3 are constants
for Equations 1, 2, and 3.
Storage stability
To assess the stability of Qu-PMs, the freeze dried Qu-
PMs were putted into 5-mL glass vials, sealed with plastic
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temperature of 30°C ± 2°C and RH of 65% ± 5% for
6 months. The formulations were evaluated for changes in
particle size, PDI, and entrapment efficiency, besides phys-
ical appearance and ease of reconstitution [31,32].
In vivo pharmacokinetics study after oral administration
To compare the pharmacokinetics of Qu-PMs with those
of pure Qu after oral administration, an animal experi-
ment was in favor of the Ethical Committee of the Sun
Yat-sen University (Guangzhou, China) and performed
in accordance with the National Institute of Health and
Nutrition Guidelines for the Care and Use of Laboratory
Animals.
Six beagle dogs (1.2 to 2.0 years of age) weighing 12 to
14 kg were acclimatized in an environmentally con-
trolled breeding room for 1 week, before fasting over-
night before the experiments, but allowed to drink water
only. These dogs were randomly distributed into two
groups each made up of three dogs. Dogs in one group
were given pure Qu dispersed in Milli Q water contain-
ing 0.3% (v/v) CMC-Na, while dogs in the other group
were administered Qu-PMs dissolved in distilled water.
All the formulations were administrated at an equivalent
dose of Qu 16 mg · kg−1 by oral gavage. Blood samples of
3 mL were collected from the hind leg vein and placed
into heparinized tubes at time intervals of 0.5, 1.0, 1.5,
2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0, and 48.0 h
after oral administration. The plasma was segregated
and the samples were kept at −20°C until analysis.
Qu was assayed using an HPLC method. In sample
analysis, a 100 μL plasma sample aliquot was blended
with protein-precipitating methanol agent (200 μL) and
0.25% HCL (100 μL) were added and vortexed for 2 min,
then heated at 50°C for 10 min. After centrifugation at
12,000 rpm for 10 min, the supernatant was analyzed by
HPLC. Qu analysis was carried out by injecting an ali-
quot (100 μL) of sample into the HPLC column (an
odyssil C18 column, 4.6 × 250 mm, 5 μm) with a precol-
umn (4.6 × 12.5 mm, 5 μm), using a mobile phase mak-
ing up of methanol 0.2% phosphoric acid (60:40, v/v) at
a flow rate of 1.0 mL · min−1. The detection wavelength
was 375 nm [33].
Pharmacokinetic parameters were estimated with one
compartmental model using the 3P87 software (pub-
lished by the State Food and Drug Administration of
China for pharmacokinetic study). The Cmax (highest
peak concentration), Tmax (the time at which Cmax
reached), and the AUC0−∞ (the total area under the
curve) were determined. The Mann-Whitney U-test
was analyzed statistically. The results of the test were
evaluated as mean values ± SD (standard deviation),
and that of p < 0.05 analysis was significant statistically
difference.Results and discussion
Preparation of Qu-PMs
Different process variables including stabilizer concen-
tration, magnetic stirring time, and theoretical drug
loading were optimized for the preparation of Qu-PMs.
Effect of stabilizer concentration
The effects of F127 concentration on the size and encap-
sulation efficiency of Qu-PMs are shown in Figure 2. As
the concentration of F127 increased (1% to 3%), the par-
ticle size of Qu-PMs increased, but the encapsulation ef-
ficiency remained almost constant at around 95%. The
particle size with 3% F127 was larger than 100 nm which
was unacceptable, and no significant difference was
found in particle size and encapsulation efficiency with
respect to 2% and 1% F127. So 1% F127 (w/v) was opti-
mized for Qu-PMs preparation.
Effect of stirring time
Qu-PMs were prepared through magnetic stirring for
particle size reduction. Figure 3 shows the decrease in
particle size upon increasing the stirring time up to 2 h.
Magnetic stirring of 2 h brought about the smaller par-
ticle size (59.32 ± 1.01 nm) and larger encapsulation effi-
ciency (95.12% ± 3.54%) compared with shorter stirring
time. So, magnetic stirring of 2 h was selected for further
research.
Optimum of drug loading
Qu-PMs were prepared with different theoretical drug
loading, i.e., 5%, 7%, and 9% of polymer, to investigate
the appropriate percentage of Qu in soluplus matrix. As
shown in Table 1, initial drug loading affected the par-
ticle size and drug encapsulation efficiency of Qu-PMs
significantly (p < 0.05). The particle size became big with
the increase of drug loading, and the encapsulation effi-
ciency also increased as drug loading increased from 5%
to 7% but decreased significantly as drug loading further
increased to 9%. Drug loading of 7% resulted in stable
PMs with higher encapsulation efficiency (95.91% ±
4.05%), optimum particle size (79.00 ± 2.24 nm), and
PDI (0.154 ± 0.044), as well as the most negative zeta po-
tential (−17.10 ± 2.30). Taking this into consideration,
the initial drug loading of 7% (w/w) was selected for Qu-
PMs formulation.
Properties of Qu-PMs
Particle size and morphology of Qu-PMs
Polymeric micelle size is a critical parameter for assess-
ment of drug preparations. Studies reported that nano-
particles with sizes around or below 100 nm showed
optimum cellular and nuclear uptake in epithelial and
smooth muscle cells [34]. In the light of this, PMs with
small size and high surface charge are expected favorable
Figure 2 Effects of stabilizer F127 concentration on size and EE of Qu-PMs (n = 3).
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as well as being evaded by the reticuloendothelial system
(RES).
The average particle size and the PDI of Qu-PMs were
studied by dynamic light scattering. The representative
size distribution of Qu-PMs (Figure 4A) clearly shows aFigure 3 Effect of magnetic stirring time on size and encapsulation enarrow size distribution with the average particle diameter
of 79.00 ± 2.24 nm and PDI of 0.154 ± 0.044. This con-
forms to the best particle size range for oral absorption.
Zeta potential measurements possessed a negative surface
charge of −17.10 ± 2.30 mV for Qu-PMs (Figure 4B),
which certainly could increase the stability of Qu-PMsfficiency (n = 3).
Table 1 Effects of initial drug loading on size, PDI, zeta potential, and EE (mean ± SD, n = 3)
Drug loading (%) Size (nm) PDI Zeta potential EE (%)
5 59.97 ± 3.70 0.183 ± 0.023 −13.4 ± 0.20 93.24 ± 3.05
7 79.00 ± 2.24 0.154 ± 0.044 −17.10 ± 2.30 95.91 ± 4.05
9 111.2 ± 3.45 0.134 ± 0.082 −15.1 ± 1.60 75.06 ± 3.19
PDI, polydispersity index; EE, encapsulation efficiency; SD, standard deviation.
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with a diameter of approximately 80 nm was examined
by TEM (Figure 4C), which is consistent with the above
results of dynamic light scattering. One major purpose
of encapsulating Qu in PMs was to enable Qu to be
completely dispersible in aqueous media, and this was
confirmed the uniform solution of Qu-PMs with an
opalescence (Figure 4D).
X-ray diffraction
The physical status of Qu encapsulated in PMs was com-
pared with that of pure Qu by XRD analysis. The XRD
patterns of pure Qu, void PMs, physical mixture of void
PMs and Qu, and Qu-PMs are shown in Figure 5. In the
figure, pure Qu exhibit a lot of distinct peaks that are
traits of a crystalline structure [35]. The physical mixture
of Qu and void PMs also present a number of distinct
peaks, indicating that Qu is crystalline in the mixture. In
the case of Qu-PMs, here were some characteristic peaksFigure 4 Size (A), zeta potential (B), TEM (C), and colloidal solution (Dof Qu observed in 17°, which indicated that the drug was
not completely amorphous in the PMs.
Fourier transform infrared spectrometer
The molecular interactions within the solid matrix of the
PMs were examined by FTIR method. On the basis of
their structure, the possible interaction between quercetin
and soluplus is hydrogen bonding, which may result in
the shifting and peak broadening of the absorption bands
at the interacting functional groups on the FTIR. The aro-
matic -OH group in quercetin might come into a hydro-
gen bond. FTIR of pure quercetin, void PMs, physical
mixture of void PMs and quercetin, and Qu-PMs are pre-
sented in Figure 6. Pure quercetin showed a number of
characteristic bands representing O-H stretching (3,700 to
3,300 cm−1), C =O absorption (1,670 cm−1), C-C stretch-
ing (1,612 cm−1), C-H bending (1,456, 1,383 and 866
cm−1), C-O stretching in the ring structure (1,272 cm−1),
and C-O stretching (1,070 to 1,150 cm−1). The existence) of Qu-PMs.
Figure 5 XRD of Qu (a), physical mixture (b), Qu-PMs (c), and
void PMs (d).
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[36]. Void PMs also show a number of bands, including
OH stretch (3,500 to 3,250 cm−1), sp3CH stretching
(2,932 cm−1), ester carbonyl stretching (1,742 cm−1), and
C =O stretching for tertiary amide (1,641 cm−1). On the
spectra of Qu-PMs, the position of carbonyl absorption
peaks in Qu-PMs was shifted to 1737.93 cm−1 and
1636.80 cm−1, respectively. However, no similar peak shift-
ing was observed in the physical mixture. These resultsFigure 6 FTIR of Qu (a), physical mixture (b), void PMs (c), and Qu-PMillustrate that there might be some interactions between
quercetin and soluplus in Qu-PMs.
Storage stability studies
The physicochemical properties of Qu-PMs containing
5% mannitol as a lyoprotectant were assessed after 6-
month storage to establish their accelerated stability.
Freeze dried Qu-PMs cakes were sealed in amber vials
and stored in a stability chamber with temperature of
30 ± 0.5°C and relative humidity (RH) of 65% ± 5% for
6 months. The freeze-dried powder of Qu-PMs was
stable without any shrinkage or collapse of the dried
cake. The encapsulation efficiency, particle size, and PDI
of the freeze dried Qu-PMs before and after storage
were comparable (Table 2). Overall, these results sug-
gested that the Qu-PMs had relatively good physical sta-
bility in the presence of mannitol under accelerated
conditions and were able to protect majority (>90%) of
the encapsulated bioactive component.
In vitro release
As quercetin is insoluble in water, it simulated gastric fluid
and intestinal fluid at room temperature (7.7, 5.4, and
28.87 μg · mL−1, respectively) [37]. Ethanol (35% (v/v)) was
used as a receptor medium to obtain a sink condition in
the dynamic dialysis study [33]. Drug release from quer-
cetin contained propylene glycol solution and Qu-PMs
suspension through the dialysis membrane at 37°C was
shown in Figure 7. The pure quercetin from the solution
showed about 96.13% release for a period of 24 h, durings (d).
Table 2 Characterization of freeze dried Qu-PMs with 5%
mannitol after 6 months of storage at 30°C ± 0.5°C and
65%± 5% RH (mean ± SD, n = 3)
Parameters Initial Final
Size(nm) 63.76 ± 2.35 65.63 ± 3.71
PDI 0.151 ± 0.023 0.183 ± 0.056
EE (%) 92.06 ± 2.41 90.36 ± 3.84
Physical appearance Intact cake Intact cake
Ease of redispersion By mere shaking By mere shaking
PDI, polydispersity index; SD, standard deviation; EE, encapsulation efficiency.
Table 3 Fitting of Qu release data from Qu-PMs into
various mechanism models
Model Equation R2
Zero-order y = 0.246 t + 8.291 0.8766
First-order ln(1 − y) = 0.004 t − 16.129 0.9311
Higuchi y = 4.018 t1/2 − 0.081 0.9894
y, accumulative release percentage; t, sampling time; R, correlation coefficient.
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from Qu-PMs. Qu-PMs suspension exhibited sustained-
release property and the accumulated release at 240 h is
only 57.78%. The sustained release may be attributed to
the diffusion of quercetin entrapped within the core of
PMs.
In addition, the release data of Qu-PMs were fitted
into different release mechanism models (Table 3). A
linear relationship was established between the Qu re-
lease rate and the square root of time (R2 > 0.98), sug-
gesting the release kinetics can be explicated by
Higuchi’s equation. Namely, Qu is released from PMs by
diffusion [38]. The reason for sustained drug release
may be the formation of hydrogen bonds between drug
and carrier molecules, which hinders the drug release.
For the same reason, quercetin was entrapped in the
polymeric micelle hydrophobic cores [39], and theFigure 7 Release of quercetin from propylene glycol solution and Qunanoencapsulation of quercetin in PMs may improve the
bioavailability of this molecule significantly.
In vivo pharmacokinetics
It has been reported that quercetin is found in plasma as
conjugates of glucuronic acid and sulfate groups [40].
Quercetin is released from the binding complex by acid
hydrolysis method, and total content of quercetin in
plasma was determined by HPLC [41]. Calibration sam-
ples were obtained by joining proper volumes of denom-
inator Qu solution in methanol into blank plasma,
gaining a calibration curve over the detected level range
of 0.10 to 8.00 μg · mL−1 (R2 > 0.99). The results of the
method validation ascertained by assessing the precision,
accuracy, recovery, and limit of quantification and
proved that the method was reliable. The bioavailability
of Qu-PMs was looked into by investigating beagle dogs
and comparing with that of pure Qu. After oral adminis-
tration of a single dose equivalent to 16 mg · kg−1 of pure
Qu or Qu-PMs, the mean quercetin concentrations in-PMs suspension.
Table 4 Pharmacokinetic parameters of quercetin in
serum after oral administration (mean ± SD, n = 3)
Parameter Pure Qu Qu-PMs
Cmax (μg/mL) 5.24 ± 1.32 7.56 ± 3.28
Tmax (h) 5.31 ± 1.08 7.02 ± 2.02
AUC0~∞(μg/h/mL) 37.68 ± 16.8 107.84 ± 54.4
T1/2 (h) 4.94 ± 2.03 10.81 ± 3.7
MRT (h) 7.18 ± 2.25 27.09 ± 7.8
F (%) 286 ± 3.23
AUC(0→∞), area under the plasma concentration-time curve calculated by the
linear trapezoidal rule from time 0 to infinity; SD, standard deviation; T1/2,
elimination half-life; Cmax, peak plasma concentration; Tmax, time to reach peak
plasma concentration.
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Figure 8 and the calculated key pharmacokinetic pa-
rameters are summarized in Table 4. The plasma level
of quercetin was detected only up to 24 h after admin-
istration of free drug, with the Cmax of 5.24 μg · mL
−1.
The drugs released from PMs were still detected in
plasma 48 h after oral administration, with the Cmax of
7.56 μg · mL−1. As shown in Figure 8, after oral admin-
istration, Qu-PMs were absorbed much slower than
pure quercetin with Tmax of 7.02 ± 2.02 h and 5.31 ±
1.08 h (p < 0.05), respectively.
What is more, the half-life (T1/2) of Qu-PMs was 2.19-
fold longer than that of pure quercetin (Table 4), indicat-
ing a maximum residence time (MRT) of quercetin in
the systemic circulation remarkably extended for Qu-
PMs after oral administration. As the AUC0–∞ value of
Qu-PMs was significantly larger than that of pure quer-
cetin, the relative oral bioavailability of Qu-PMs calcu-
lated from AUC0–∞ values was about 286% (p < 0.05)
comparing with pure quercetin. These results implied an
enhanced bioavailability of quercetin was achieved
through incorporation of drug into PMs.
The main purpose of this study was to prepare an
aqueous formulation which could improve the oral bio-
availability of the hydrophobic quercetin. In this regard,
a nanocarrier system based on soluplus PMs was devel-
oped in this study and as anticipated, the pharmacoki-
netic results indicated the bioavailability of the delivered
quercetin was enhanced. When administered via oral
route, PMs may be absorbed through specialized M-cells
of the Peyer’s patches in the small intestine [1]. Though
the PMs showed the potential to enhance the oralFigure 8 Mean quercetin plasma concentration.bioavailability of poorly water-soluble drugs, the under-
lying mechanisms of enhancement, however, are still un-
clear and provoke future research interests.Conclusions
Quercetin was loaded into nanosized polymeric micelles
based on amphiphilic polymers soluplus using a modified
film dispersion method. The stable Qu-PMs showed sus-
tained release of entrapped quercetin for up to 10 days
in vitro, and more importantly, a sustained plasma level
and enhanced systemic bioavailability of quercetin in vivo.
Thus, the Qu-PMs provide a promising carrier candidate
with efficient delivery of quercetin for therapeutic treat-
ment in near future. Moreover, this study explores an in-
teresting alternative approach for design and fabrication
of novel polymeric micelles as delivery systems for bio-
active compounds.
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